ALX Oncology Holdings Inc revenue

ALX Oncology Holdings Inc's revenue was $0 in fiscal 2022.

Revenue history

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

ALX Oncology Holdings Inc: revenue history, annual
Fiscal year	2018Dec 2018	2019Dec 2019	2020Dec 2020	2021Dec 2021	2022Dec 2022
Revenue	2,067	4,796	1,182	0	0
Growth on the year before	—	+132.0%	−75.4%	−100.0%	—

US$ thousands unless shown otherwise. Fiscal quarters.

ALX Oncology Holdings Inc: revenue history, quarterly
Quarter	2019 Q2Jun 2019	2019 Q3Sept 2019	2019 Q4Dec 2019	2020 Q1Mar 2020	2020 Q2Jun 2020	2020 Q3Sept 2020	2020 Q4Dec 2020
Revenue	1,295	1,256	1,213	655	527	0	0
Growth on the same quarter a year before	—	—	—	—	−59.3%	−100.0%	−100.0%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

Company	Revenue	Growth	3-year growth a year
ALX Oncology Holdings Inc	$1.2m	—	—
Longeveron Inc.	$1.2m	-42.7%	10.4%
Dare Bioscience, Inc.	$1.4m	4366.5%	—
Shattuck Labs, Inc.	$1.0m	-66.6%	5.2%
Cartesian Therapeutics, Inc.	$1.5m	44.0%	-68.8%
Medicinova Inc	$920,481	875.7%	—

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from ALX Oncology Holdings Inc's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to ALX Oncology Holdings Inc.